The Dosage Form Decision: Why Form Matters as Much as Ingredient

The Dosage Form Decision: Why Form Matters as Much as Ingredient

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

For most supplements the dosage form changes the outcome as much as the ingredient. The same active can land in the bloodstream within minutes from one format and over an hour from another, because the body sees a polymer film, a capsule, a softgel, and a gummy as four different pharmacokinetic problems. A 2023 JAMA analysis of melatonin gummies found 88 percent inaccurately labeled, from 74 to 347 percent of the claim (Cohen et al.). An oral dissolving strip (ODS) is one mucosa-first answer. MIHIYO Labs selects the strip format when route precision, water-free dosing, and low-dose accuracy are the binding constraints, not when the ingredient simply needs more vehicle.

Does the dosage form really matter as much as the ingredient?

Most of the time, yes. A milligram of caffeine, melatonin, or 5-HTP is identical at the molecular level no matter which format carries it. What differs is the route the molecule takes from your mouth to your blood, the time it takes to get there, and how reliably the labeled dose actually arrives. Twelve articles into this comparison series, the pattern is too consistent to keep treating the format as a packaging choice. An oral dissolving strip (ODS), a capsule, a softgel, a chewable, a gummy, an effervescent tablet, a tincture, and a sublingual spray each ask the body a different pharmacokinetic question.

The cleanest example is melatonin. Cohen and colleagues analyzed 25 US melatonin gummy products and found that 22 of them — 88 percent — were inaccurately labeled, with measured melatonin content ranging from 74 to 347 percent of the label claim.1 The same milligram on the label became three different milligrams in the customer's hand depending on which gummy they happened to pick up. That is not an ingredient problem. It is a dosage-form problem.

I have come back to this question every week of this series because it is the question I have to answer when I formulate. The ingredient list is the easy half.

What changes when you change the form?

Four things change, and they change together.

The absorption route. A capsule or a swallowed tablet has to disintegrate, empty into the intestine, and survive hepatic first-pass metabolism before its active reaches systemic circulation.23 An ODS hydrates against the oral mucosa and can release part of the dose directly into venous return that bypasses the portal vein.45 For high-extraction molecules the gap that creates is enormous; for low-extraction molecules it is small. Either way, the route is the lever that does the work.

The onset. Even when total bioavailability is similar, when the dose starts to land matters. Caffeine is the textbook case. Whole-capsule caffeine reaches peak plasma concentration roughly an hour after dosing in pooled PBPK modeling.6 Caffeine chewing gum, which puts the molecule against the buccal mucosa during chewing, was absorbed significantly faster than capsules in a controlled crossover study.7 The total caffeine ends up the same. The clock to "feels working" does not.

Dose precision. A unit-dose film or capsule fixes the dose at manufacture. A dropper, a spray, or a hot-fill gummy fixes it again at every use. Elliott and colleagues found that household droppers underdosed by a mean of 33 percent compared with the labeled volume in their dosing-accuracy study.8 The JAMA melatonin gummy survey, again, showed actual content ranging from 74 to 347 percent of the label.1 Unit-dose film and unit-dose capsule formats do not have those failure modes.

The user step. Different forms ask the user to do different work. A whole tablet asks for water and the ability to swallow. A chewable asks for mastication; Lopez and colleagues note in their pediatric oral-drug-delivery review that release from many chewables depends on chewing ability and behavior.9 An ODS asks for placement on the tongue or against the cheek and patience for 20 to 60 seconds. None of these are hard, but they are different sources of variability.

Four common supplement dosage forms ask the body four different pharmacokinetic questions A single labeled milligram dose follows four different absorption paths through capsule, softgel, gummy, and oral dissolving strip formats, ending at different points in gut, liver, and bloodstream. 1 mg labeled dose Same molecule, four formats Capsule Gut + first-pass ~1 h to peak Bloodstream Extended release Softgel Shell rupture + gut Oil carrier dependent Bloodstream High-payload friendly Gummy Chewed + gut 88% mislabeled (JAMA 2023) Bloodstream Dose varies per piece Oral dissolving strip Oral mucosa 30 to 60 s disintegration Bloodstream Low-dose precision Stage with absorption-rate or dose-accuracy trade-off Mucosa-first route with fixed unit dose Source: Cohen 2023 (JAMA); Kamimori 2002; Hoffmann 2011; Damian 2021. Same labeled milligram, four different pharmacokinetic problems.

What the studies show when you line the forms up

The comparison series this article closes out gives us seven matched pairs against the ODS. Pulling the headline finding out of each is the clearest way to see how the form choice changes the outcome.

Comparison What changes vs. ODS Source
Capsule Caffeine in gum-style buccal contact absorbs faster than swallowed capsules; gut + first-pass extends onset Kamimori et al., 2002
Compressed tablet Tablets must disintegrate; in-vivo gastric disintegration averaged 10 to 26 minutes vs an ODS in 30 to 60 seconds Fredholt et al., 2022; Hoffmann et al., 2011
Softgel Gelatin shell must swell and rupture before release; oil-soluble actives still face partial first-pass Damian et al., 2021
Chewable tablet Release depends on chewing ability; chewed aspirin shortened 50% platelet inhibition from 12 to 5 min, but route stays GI Feldman & Cryer, 1999; Lopez et al., 2015
Gummy 88% of US melatonin gummies were inaccurately labeled (74-347% of claim) Cohen et al., 2023
Effervescent tablet Speeds gastric emptying but adds sodium; +16% odds of cardiovascular events in 1.29M-adult BMJ cohort George et al., 2013
Sublingual spray Spray dose depends on actuation; oral films hold a fixed dose and adhere to mucosa Visser et al., 2015
Measured melatonin content versus label claim across 25 US melatonin gummy products In a 2023 JAMA analysis by Cohen et al., 22 of 25 melatonin gummies were inaccurately labeled, with actual melatonin content ranging from 74 to 347 percent of the label claim. 0% 100% 200% 300% 400% 100% = label-accurate Melatonin gummies — measured vs label claim 25 US products, 22 inaccurate. Cohen et al., JAMA, 2023. 25 melatonin gummy products (ordered for display) Inaccurate: 22 of 25 (88%). Range: 74% to 347% of label. Reference line at 100% marks label-accurate dose. Bars are illustrative; per-product values are reported in Cohen et al. (2023). ~90-110% of label 80-125% (bioequivalence band) Outside 80-125%

The rows do not say "ODS wins seven times." They say the trade-off changes seven times. The chewable tablet wins when the payload is heavier and the user just dislikes whole pills. The softgel wins when the molecule is oil-soluble and the dose is larger than a film can comfortably hold. The effervescent tablet wins when speed of gastric absorption is the only goal and the user is healthy enough that the sodium load does not matter. The capsule wins when extended-release behavior is what the formula was built for.

The ODS wins when the molecule is potent at low dose, the onset has to start at the mouth rather than after a gastric delay, the user wants no water, and the labeled dose must equal the delivered dose every time.

That last criterion is the one I find hardest to overstate. Cohen's JAMA paper is not a paper about melatonin chemistry. It is a paper about a form that makes consistent dosing structurally difficult. When the form is the variable, the molecule becomes hard to study, hard to recommend, and hard to compare across brands.

What this means for the MIHIYO product range

The dosage form decision is the spine of how I think about each of our three ODS products.

For Energy-Focus, the question is not whether the strip "beats" coffee or a caffeine capsule. Caffeine is well absorbed by every oral route.6 The question is whether the format gets earlier mucosal contact and a more portable, water-free dose at a tightly defined caffeine load. That is a film question, not an ingredient question.

For Sleep-Support, the question is whether a low melatonin dose can be delivered consistently to a mucosa-aware route. The EFSA-authorized claim for reducing sleep onset latency starts at 1 mg taken close to bedtime; clinical pharmacokinetic reviews report wide variability in oral melatonin absorption.1011 A precision low-dose film matches the dose-response shape of the molecule better than a 5 mg or 10 mg gummy that may or may not contain what it says it does.

For Mood-Boost, the form question is more modest. 5-HTP and L-theanine do not need transmucosal delivery to work. The film still helps with dose precision and a no-water daily ritual, but I would not oversell route differences here. The ingredient logic carries more of the load than the form does.

That is the point. The right answer is not "use the strip for everything." It is "let the molecule and the use case pick the form."

For readers comparing adjacent formats one pair at a time, the strip versus capsule and strip versus gummy pieces work well as entry points; the rest of the comparison series builds the full table above.

Where the dosage-form-first view falls short

The argument cuts both ways. There are real limits to the "form matters as much as ingredient" claim.

First, not every ingredient is route-sensitive. Caffeine has near-complete oral bioavailability in pooled PBPK analysis, so the gain from a mucosal route is mostly onset, not exposure.6 Calling that a major bioavailability advantage would be overclaiming. The same is true for many vitamins and minerals at conventional doses.

Second, the ODS format is bounded by payload. A thin film cannot comfortably carry hundreds of milligrams of a low-potency ingredient. For fish oil, vitamin D3 at high dose, or any bulk nutrient, the softgel or the chewable is the right industrial answer.12

Third, the labeled dose does not always equal what the body sees, even from a "clean" form. A capsule with poor disintegration, a film with a permeation-resistant active, or a sublingual spray aimed past the mucosa all fail in their own ways. Form choice raises the ceiling. It does not lock in a result.

Finally, I do not want to leave the impression that ingredient quality is solved. The right answer is not "trust the film." The right answer is "match the ingredient, the form, and the dose to each other, and verify each independently."

The bottom line

Across twelve articles of side-by-side comparisons, the dosage form decision keeps coming first. For an ingredient that benefits from mucosal contact, low dose precision, water-free dosing, and a short onset window, the oral dissolving strip is the cleanest match. For an ingredient that needs payload, lipid carrier, or extended release, another form is the cleaner answer. The mistake is treating the form as a packaging detail. For supplements priced and marketed to be taken daily, the form is doing as much pharmacological work as the molecule.

References

  1. Cohen PA, Avula B, Wang YH, Katragunta K, Khan I. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. 2023;329(16):1401-1402. PMID: 37097362. DOI: 10.1001/jama.2023.2296. <https://pubmed.ncbi.nlm.nih.gov/37097362/>
  2. Bartlett JA, van der Voort Maarschalk K. Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine. AAPS PharmSciTech. 2012;13(4):1110-1115. PMID: 22936407. DOI: 10.1208/s12249-012-9839-7. <https://pubmed.ncbi.nlm.nih.gov/22936407/>
  3. Fredholt F, Di Meo C, Sloth S, Müllertz A, Berthelsen R. Gastrointestinal in vivo disintegration profiles of immediate-release dosage forms. Eur J Pharm Biopharm. 2022;181:84-92. PMID: 36122785. DOI: 10.1016/j.ejpb.2022.09.012. <https://pubmed.ncbi.nlm.nih.gov/36122785/>
  4. Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8(3):299-316. PMID: 21284577. DOI: 10.1517/17425247.2011.553217. <https://pubmed.ncbi.nlm.nih.gov/21284577/>
  5. Jacob S, Nair AB, Patil A, Boddu SHS. An Updated Overview of the Emerging Role of Patch and Film-Based Buccal Delivery Systems. Pharmaceutics. 2021;13(8):1206. PMID: 34452167. DOI: 10.3390/pharmaceutics13081206. <https://pubmed.ncbi.nlm.nih.gov/34452167/>
  6. Grzegorzewski J, Bartsch F, Köller A, König M. Pharmacokinetics of caffeine: A systematic analysis of reported data for application in metabolic phenotyping and liver function testing. Front Pharmacol. 2022;12:752826. PMID: 35280254. DOI: 10.3389/fphar.2021.752826. <https://pubmed.ncbi.nlm.nih.gov/35280254/>
  7. Kamimori GH, Karyekar CS, Otterstetter R, Cox DS, Balkin TJ, Belenky GL, Eddington ND. The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int J Pharm. 2002;234(1-2):159-167. PMID: 11839447. DOI: 10.1016/S0378-5173(01)00958-9. <https://pubmed.ncbi.nlm.nih.gov/11839447/>
  8. Elliott JP, McConaha J, Cornish N, Bunk E, Hilton L, Modany A, Bucker I. An Assessment of Caregiver and Child Knowledge and Accuracy of Pediatric Liquid Medication Dosing. J Pharm Technol. 2014;30(4):113-117. DOI: 10.1177/8755122514533780. <https://journals.sagepub.com/doi/10.1177/8755122514533780>
  9. Lopez FL, Ernest TB, Tuleu C, Gul MO. Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms. Expert Opin Drug Deliv. 2015;12(11):1727-1740. PMID: 26165848. DOI: 10.1517/17425247.2015.1060218. <https://pubmed.ncbi.nlm.nih.gov/26165848/>
  10. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency. EFSA Journal. 2011;9(6):2241. DOI: 10.2903/j.efsa.2011.2241. <https://www.efsa.europa.eu/en/efsajournal/pub/2241>
  11. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71(8):901-909. PMID: 26008214. DOI: 10.1007/s00228-015-1873-4. <https://pubmed.ncbi.nlm.nih.gov/26008214/>
  12. Damian F, Harati M, Schwartzenhauer J, Van Cauwenberghe O, Wettig SD. Challenges of Dissolution Methods Development for Soft Gelatin Capsules. Pharmaceutics. 2021;13(2):214. PMID: 33557167. DOI: 10.3390/pharmaceutics13020214. <https://pubmed.ncbi.nlm.nih.gov/33557167/>
  13. George J, Majeed W, Mackenzie IS, MacDonald TM, Wei L. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. BMJ. 2013;347:f6954. PMID: 24284017. DOI: 10.1136/bmj.f6954. <https://pubmed.ncbi.nlm.nih.gov/24284017/>
  14. Visser JC, Woerdenbag HJ, Crediet S, Gerrits E, Lesschen MA, Hinrichs WLJ, Breitkreutz J, Frijlink HW. Orodispersible films in individualized pharmacotherapy: the development of a formulation for pharmacy preparations. Int J Pharm. 2015;478(1):155-163. PMID: 25448577. DOI: 10.1016/j.ijpharm.2014.11.013. <https://pubmed.ncbi.nlm.nih.gov/25448577/>
  15. Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol. 1999;84(4):404-409. PMID: 10468077. DOI: 10.1016/S0002-9149(99)00324-0. <https://pubmed.ncbi.nlm.nih.gov/10468077/>

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.